abstract OBJECTIVES: To describe the demographic and clinical characteristics of pediatric multiple sclerosis (MS) in the United States.
Multiple sclerosis (MS) is a central nervous system autoimmune inflammatory demyelinating disease. Generally considered a disease of young and middle-aged adults, an estimated 2.7% to 5.4% of all patients with MS experience their first attack before 18 years of age. [1] [2] [3] [4] [5] [6] [7] [8] Initial descriptions of childhood-onset MS appeared in case reports and small case series. [9] [10] [11] [12] Greater awareness and interest led to increased publications, including larger case series, reports from single institutions, multicenter studies, and national and population-based surveys. [1] [2] [3] [4] [5] [6] [7] [8] [13] [14] [15] [16] [17] Pediatric-onset MS (pediatric MS) was compared with adult-onset MS in a few publications. 5, 7, 17, 18 However, because pediatric MS is a comparatively rare disorder (frequency of 0.2 to 0.64/100 000), 7, [19] [20] [21] [22] most investigations have been limited by relatively small sample sizes, retrospective data, or both. Studies with >150 subjects are few (and only 1 had 300 subjects). 16, 17 In addition, most comprised homogeneous populations in terms of race and ethnicity.
It is unclear if findings from these studies are generalizable to larger, more diverse populations and if there are differences between children with disease onset before 12 years of age compared with those with onset at age ≥12 years. The aim of the present multicenter study was to better define the demographic and clinical characteristics of pediatric MS in the United States, with an emphasis on contrasting features of younger versus older children. This extremely large sample provides an opportunity to examine subsets of patients according to age of onset as well as the influence of more specific demographic (ie, country of origin of parents) and clinical (ie, presence of encephalopathy, possible hormonal influences, timing of menarche in relation to MS onset) features, in addition to more customary MS parameters (ie, initial MS symptoms, relapse frequency).
METHODS

Data Acquisition
This analysis included longitudinally collected data from the US Network of Pediatric MS Centers, Pediatric MS and Other Demyelinating Diseases, database. 
Participating centers included
Statistical Analysis
Demographic characteristics and clinical features of the study population were described by using counts and relative frequencies for categorical variables and means ± SDs or medians and interquartile ranges for numeric variables. Characteristics were compared between age groups by using Fisher's exact tests or Wilcoxon ranksum tests. Due to varying rates of unknown data, we report the number of patients with available data for each description.
Disease onset was defined as the date of first clinical attack, signs, or symptoms. Clinical features reported at disease onset are described, including symptoms, localization, and cerebrospinal fluid (CSF) profile when available. The number of patients with an elevated immunoglobulin G index and/or presence of oligoclonal bands at any time between the first symptoms and last clinic visit is also described. Clinical features were compared between age groups by using Fisher's exact test and the Wilcoxon rank-sum test.
Clinical Assessment
Data were collected by using uniform definitions of MS relapses 24 ; EDSS scores were measured in accordance with the Neurostatus Definitions and Scoring. 25 Because of variation in the timing between disease onset and the first visit to the network clinical center, we summarized EDSS scores at 2 years' postonset in addition to EDSS scores from the first visit to the clinical center. EDSS scores were compared between age groups (<12 years versus ≥12 years at onset) by using Wilcoxon rank-sum tests.
For patients presenting to a center within 3 years of MS onset, relapse rates were calculated as the number of relapses in the sample divided by the number of follow-up patientyears. Separate rates were also calculated for the first 2 years after onset and for relapses occurring >2 years after onset. All reported attacks (relapses), not including the first attack, are included in calculations.
Rates were compared between age groups by using negative binomial regression models.
We described the frequency of disease-modifying therapy (DMT) use overall and according to age groups, and estimated the median and 25th and 75th percentiles of the time interval between MS diagnosis and initiation of DMT by using survivor functions. Patients who had not begun DMT at their most recent visit were considered censored. Time to DMT was compared between age groups by using a log-rank test.
Analyses were conducted by using SAS version 9.4 (SAS Institute, Inc, Cary, NC).
RESULTS
Demographic Features
Age and Sex at Disease Onset
A total of 490 children and adolescents (324 girls, 166 boys) with MS met study criteria. Table 1 presents the demographic characteristics of the cohort.
The age of disease onset for both boys and girls is presented in Fig 1. Girls had a slightly higher average age at onset. Symptom onset occurred before age 12 years for 139 patients (28%) and at age ≥12 years for 351 (72%) patients. Overall, the ratio of femaleto-male subjects was 1.95 to 1. The highest frequency for first events for both sexes occurred in adolescence, with peaks at age 15 years for girls and age 16 years for boys. However, from age 8 years onward, female subjects exceeded male subjects in each year. The sex difference in onset of disease was most prominent in patients from age 12 to 17 years.
Onset of MS symptoms occurred before menarche for 22% of girls; 78% of girls had MS symptom onset postmenarche. The mean ± SD age of menarche was 11.6 ± 1.4 years (range, 7-15 years) in girls with MS symptom onset postmenarche. In contrast, in girls with MS symptom onset before menarche, the mean age of menarche was 12.2 ± 1.3 years (range, 10-15 years).
In girls with MS symptom onset postmenarche, 10% reported menarche at the same age as MS onset; 26% reported a menarchal age of 0 to 1 years before MS symptom onset, and 44% reported a menarchal age within 0 to 2 years of MS symptom onset.
Race and Ethnicity
Race and ethnicity were selfdefined by 92% and 94% of cases, respectively. As shown in Table 1 , most individuals identified as either white (67%) or African American (21%). Almost 70% self-identified as non-Hispanic/non-Latino. Race and ethnicity did not differ according to sex.
Ancestry
Ninety-four percent of the patients were born within the United States. For the 30 children who were not, 6 were born in Central or South America, 6 in Asia, 6 in Europe, 5 in the Caribbean, 5 in the Middle East, and 2 in Africa or Oceania (Fig 2) .
Of note, 39% of the patients with pediatric MS were second-generation 3 (Fig 2) .
Family History of MS and Other Autoimmune Diseases
MS in family members was reported at the time of the first clinic visit. Five percent of the cohort had a family member with MS, including siblings (1%), parents (3%), and grandparents (2%). Other autoimmune diseases in the family were reported by 35% of patients, most frequently among grandparents (21%) and least among siblings (5%). Thyroid diseases (including Hashimoto's and Grave's disease, 14%), rheumatoid arthritis (11%), inflammatory bowel disorders (5%), and systemic lupus erythematosus (2%) were the most frequent conditions (Supplemental Table 3 ).
Clinical Features According to Age of Onset
Features of First Attack
As shown in Table 2 , many features differed between those aged <12 years (younger age group) compared with those aged ≥12 years. Antecedents were more frequent among the younger group (P < .001) with previous infection the most common. Encephalopathy, constitutional symptoms, and coordination problems were more frequent among the younger children while sensory symptoms were more frequently reported by older children. The only anatomic localization that differed between age groups was the higher proportion of older children with a spinal cord localization (P < .001).
The first documented CSF profile exhibited an elevated cell count in both age groups, with no significant difference, but the percentage of neutrophils was significantly higher and the lymphocyte counts significantly lower in the younger group. Rather striking group differences were noted for greater frequency of oligoclonal bands and elevation of the immunoglobulin G
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FIGURE 1
Age distribution, according to sex, of pediatric-onset MS patients at the time of fi rst event.
FIGURE 2
Country of birth among pediatric-onset MS patients and their parents. Patients (n = 27) and parents (n = 102) with missing birth country data are excluded. 
Treatment
Overall, 75% of the cohort received DMT at some time during the study (Supplemental Table 4 ). The interval between diagnosis and start of DMT was delayed among the younger children relative to the older children. Among those <12 years of age, median time from diagnosis of MS to initiation of DMT was 178 days vs 78 days among patients ≥12 years of age (log-rank test, P = .002). For categorical characteristics, the number of patients with the characteristic and the number of patients with available data are shown as a fraction, along with the calculated percentage. For continuous measures, the number of patients with available data is shown along with the mean ± SD. For relapse rates, the number of patients, the total number of events, and the total number of patient-years of follow-up are shown along with the estimated annualized relapse rate (ARR) and SE. We noted that 17% of patients seen at our centers had a young age of onset (ie, <10 years), a considerably higher proportion than reported from the only other study of >300 children with MS (a multicenter investigation conducted in France and Belgium) in which just 7.6% had disease onset before age 10 years and only 18% by age 12 years. 17 Among our youngest cases, there was an almost equal sex ratio (girls only slightly outnumbered boys). Female preponderance increased with age, particularly in adolescence, in agreement with other reports. A novel finding from our database is that 44% of girls with postmenarchal MS onset reported a menarchal age within 0 to 2 years after age at MS symptom onset. Consistent with 2 recent reports of smaller cohorts, the observed temporal link between onset of menarche and MS in our sample supports the potential role of sex hormones in the complex immunologic process occurring in the onset of MS in adolescent girls. 28, 29 Clinical features that distinguished younger versus older MS cases included the following: younger children were more likely to report a prodromal event before the first MS attack, present with encephalopathy, and have more motor and coordination problems. In contrast, older children had more sensory symptoms suggesting spinal cord involvement (similar to findings recently reported from Germany comparing 47 children aged <11 years with those >14 years of age, 30 and more consistent with findings reported for adult-onset MS). 31 Younger versus older children had a slightly different CSF profile interpreted as manifesting a more prominent role in the innate immune response (confirming our previous observations in a smaller cohort). 32 Although the frequency of DMT treatment was similar between younger and older children, there was a delay among younger children in reaching an MS diagnosis and after diagnosis in starting DMT.
DISCUSSION
In addition to having an opportunity to study younger versus older children with MS, our pool of patients drawn from multiple geographic areas of the United States offered an opportunity to evaluate the selfreported racial, ethnic, and heritage characteristics. In contrast to the predominantly white and principally of Northern European heritage noted for adult-onset MS in the United States, our pediatric cohort had a relatively lower proportion of white and a higher proportion of AfricanAmerican and Hispanic/Latino cases corroborating preliminary observations in smaller samples from our group and others. 7, 20, 33 In addition, we found a surprisingly high proportion of second-generation Americans (United States nativeborn children whose parents were foreign-born). Although parent-origin countries were diverse, Mexico, Central American, and Caribbean countries predominated. Similar trends were noted in another North American study. A pediatric MS sample from Canada found that patients were less likely to report European ancestry and more likely to report Asian, Middle Eastern, or Caribbean ancestry relative to the adult-onset MS Canadian sample. 34 Reasons for the current differences between the pediatric and adultonset MS population in the United States are not totally clear. The increase in racial/ethnic diversity may simply reflect the current changing and increasing diversity of the population of US children (ie, a mirroring the change and shift in the ethnic distribution of the general population), manifesting the increased wave of immigrants with a concomitant increased proportion of second-generation children. 26, 27 The broader racial/ethnic diversity in pediatric MS versus adult-onset MS populations may also reflect the increased migration from low MS incident areas to the higher MS North American incident area. This ethnic and racial diversity is complex, as emphasized by our preliminary report using a genetic ancestry marker. 35 A combination of genetic and environmental influences both independently and interactively may help explain those findings.
There are several limitations to our study, including potential source of selection bias, as most but not all centers are located in large urban areas (areas often are composed of a more racially and ethnically diverse population than more rural areas), which could have led to an overrepresentation of immigrants and minority groups. 26, 27 It is possible that sicker children with active disease were preferentially referred to the centers. However, the sample's lower relapse rate than reported in other studies 36 does not support the conclusion that sicker patients were overrepresented. Conversely, incomplete patient recall could have led to a lower reported relapse rate. The possibility of incomplete memory bias was addressed by limiting the analyses to only those patients evaluated at the centers within 3 years of symptom onset. The early and widespread initiation of DMT in the patients could also have accounted for a lower than expected relapse rate.
The strengths of the study are its longitudinal and multicenter design, use of common data capture with enrollment of a large ethnically and racially diverse sample allowing analysis of subgroups based on age of onset.
CONCLUSIONS
Our findings suggest that a more diverse heritage, racial, and ethnic composition among those with pediatric-onset MS should be followed up with studies of genetic markers. The observation that the younger patient group exhibits clinical features distinct from the older children, and had a longer time to diagnosis and time to begin DMT, deserves attention. Further recognition of clinical features in younger MS patients should help close the gap in diagnosis and treatment relative to their older counterparts.
